Cargando…
Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for cancer. Due to the mechanism of action of ICIs, inflammatory reactions against normal tissue were an anticipated side effect of these agents; these immune‐related adverse events have been documented and are typically lo...
Autores principales: | Neilan, Tomas G., Rothenberg, Mace L., Amiri‐Kordestani, Laleh, Sullivan, Ryan J., Steingart, Richard M., Gregory, William, Hariharan, Subramanian, Hammad, Tarek A., Lindenfeld, JoAnn, Murphy, Martin J., Moslehi, Javid J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156187/ https://www.ncbi.nlm.nih.gov/pubmed/29802220 http://dx.doi.org/10.1634/theoncologist.2018-0157 |
Ejemplares similares
-
Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document
por: Ammirati, Enrico, et al.
Publicado: (2020) -
Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions
por: Moslehi, Javid, et al.
Publicado: (2022) -
Assessing cardiac safety in oncology drug development
por: Seltzer, Jonathan H, et al.
Publicado: (2019) -
21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine
por: Sheng, Calvin Chen, et al.
Publicado: (2016) -
Smoldering myocarditis following immune checkpoint blockade
por: Norwood, Timothy G., et al.
Publicado: (2017)